About the Peptide Therapeutics Database
The renewed interest in peptide therapeutics in the biopharmaceutical industry has prompted the Peptide Therapeutics Foundation in collaboration with the Tufts Center for the Study of Drug Development (Tufts-CSDD) to generate a comprehensive database of all the peptide new chemical entities (NCEs) that have been approved and/or have entered clinical development worldwide during the past 60 years. This database which is now being made available for purchase is an invaluable tool for researchers and managers involved in peptide research, development, marketing, finance, and business development.
The database was generated using public information disclosed by pharmaceutical and biotechnology firms involved in the development of peptide therapeutics. Classification as a peptide required that each NCE was composed of a minimum of two adjacent amino acids coupled together through an amide bond. No maximum number of amino acids was defined for synthetic peptides however a maximum length of 50 amino acids was imposed for recombinant peptide candidates. Peptides produced via fermentation (e.g., certain peptide antibiotics) were not included in the data set.
The database currently includes 334 entries documenting information such as: INN and/or compound name; indications studied; current development status of the first/most advanced clinical indication; size of peptide (number of amino-acids); topology (linear, cyclic); manufacturing method (synthetic or recombinant) and molecular target. Data were collected from public sources including but not limited to: company web sites, press releases, annual reports, meeting reports, investor presentations, clinicaltrials.gov, biomedical literature, Drugs@fda and emea.europa.eu. Where necessary the information was cross-referenced with public information available in a variety of commercial databases (e.g., IDdb3, Adis Insight, IMS R&D Focus, PharmaProjects, NDA Pipeline). A final manual curation was performed to address any inconsistency between the different data sources.
The 2010 edition of the Peptide Therapeutics Database is now available for purchase as a pdf document through the Peptide Therapeutics Foundation. Click here for pricing details.
The creation and annual updates of the Peptide Therapeutics Database is made possible though a grant of the Peptide Therapeutics Foundation underwritten by Amylin Pharmaceuticals, Ferring Research Institute, Ipsen and PolyPeptide Group.
About the Development Trends for Peptide Therapeutics Report
The ‘Development Trends for Peptide Therapeutics’ report is an analytical assessment of the data set contained in the Therapeutic Peptides Database performed by Dr. Janice Reichert, Sr. Research Fellow at the Tufts Center for the Study of Drug Development (Tufts-CSDD). The main findings of the 2010 report include:
- An increase in approved peptide NCEs in recent years both in the US and rest of the world, some of which have been significant commercial successes
- A marked increase in the number of peptide NCEs entering clinical development in recent years
- An increase in the size of peptides being developed
- The evolution of synthetic manufacturing methods that correlates with an increase in the size of peptides
- Increased diversity of molecular targets and therapeutic areas
- Relatively high development success rates, significantly superior to those reported for small molecule NCEs and similar to those reported for biologics.
The 2010 edition of Development Trends for Peptide Therapeutics report is now available for purchase through the Peptide Therapeutics Foundation. Click here for pricing details.
The bi-annual updates of the Development Trends for Peptide Therapeutics report is made possible though a grant of the Peptide Therapeutics Foundation underwritten by Amylin Pharmaceuticals, Ferring Research Institute, Ipsen and the PolyPeptide Group.